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Abstract (250 words) 
Background  With changes in diagnosis, treatment and management of breast cancer since the 
mammography screening trials, there is a need to evaluate contemporary breast screening 
programmes.  A case-control study was set up to assess the current impact of attendance in the 
English Breast Screening Programme on breast cancer mortality. 
Methods  Cancer registry cases who died from primary breast cancer aged 47-89 in London in 2008-
2009 (869 women) were matched to 1 or 2 general population controls (1,642 women) with no 
diagnosis of breast cancer at the time of the case’s diagnosis, who were alive at the case’s death. 
Cases and controls were matched for date of birth and screening area, and had been invited to 
breast screening at least once prior to the case’s diagnosis. Odds ratios (OR) were estimated using 
conditional logistic regression. Self-selection bias was addressed using contemporaneous attendance 
at the cervical screening programme. Sensitivity analyses were undertaken to assess the likely effect 
of lead time bias. 
Results  Attendance at breast screening resulted in a breast cancer mortality reduction of 36% 
(OR=0.64, 95%CI 0.45-0.88) after self-selection correction. Attendance in the last 3 years prior to 
diagnosis resulted in a 61% mortality reduction (OR=0.39, 95%CI 0.30-0.50). Lead time bias effects 
were negligible. 
Conclusion  Our results suggest that community breast screening programmes provide their 
expected benefit in terms of reducing the risk of breast cancer death among women participating. 
Impact  Mammography is an important tool for reducing  breast cancer mortality and its impact 
could be increased by encouraging regular attendance. 
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Introduction 
Following results of two randomised controlled trials (RCTs) of population mammographic screening 
(1),(2), the UK National Health Service Breast Screening Programme (NHS BSP) was implemented in 
1988 inviting women aged 50–64 to attend mammographic screening every 3 years. In 2001, this 
was extended to include women aged 65-70, and the impact of expanding it to invite women aged 
47 to 73 is currently being trialled (3),(4). 
Breast cancer remains the most commonly diagnosed cancer among women in the UK, accounting 
for a third of all female cancer cases, and the second most common cause of female cancer death 
(5). 
There are two motivations for the ongoing evaluation of mammographic screening programmes, 
with particular reference to their effect on breast cancer mortality. The first relates to the 
monitoring and audit of specific programmes, to ensure that they are delivering their clinical aim, 
and to improve quality where they are not. The second more general reason is that, as has been 
argued in a number of high profile publications (6),(7), the RCTs of mammography screening took 
place several decades ago, before the epoch of effective adjuvant systemic therapies and the 
introduction by many healthcare providers of multidisciplinary management of cancer care, 
including through multidisciplinary care teams (MDT) or tumor boards meetings in the US (8). These 
changes have led in turn to improved survival in breast cancer patients. Thus, there remains the 
question of whether the intervention of early detection is still necessary when prognosis has 
improved for breast cancers of all stages (9),(10). In addition, there have been changes to the 
mammography screening test since the RCTS, such as the introduction of two-view mammography 
(11), and to referral policies and practices with respect to breast symptoms (12). An estimate of the 
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effect of breast cancer screening on mortality from the disease in the twenty-first century is 
therefore of value to both healthcare providers and consumers. 
The case-control approach to evaluation of cervical screening has been particularly productive (13, 
14). In breast cancer screening, estimates from case-control studies have been shown to be in 
reasonable agreement with RCT estimates, providing adequate adjustment/correction is made 
(15),(16),(17). Case-control studies of the effect of screening on breast cancer mortality are 
potentially prone to self-selection bias whereby  women who choose not to comply are generally 
thought to have a higher underlying risk of breast cancer death, as had been observed in the analysis 
of the 1980’s trial data (18),(19). Case-control studies of the effect of screening on breast cancer 
mortality also suffer from lead time, the amount of time by which the date of diagnosis of the case 
has been advanced by screening;, i.e. the screen at which a case is diagnosed will be counted as 
screening exposure, whereas a screen which occurred after the case diagnosis (but prior to the date 
on which it would have been diagnosed symptomatically) for a matched control will not. This may 
confer a bias against screening due to the lesser opportunity for screening among healthy women 
(controls). 
Using the case-control design, attendance at breast screening has been reported to halve breast  
cancer mortality risk across Europe and Australia after correcting for self-selection (reviewed in 
(7),(20),(21)). 
In this article, we report the results from a case-control study which included primary breast cancer 
deaths that occurred in 2008 and 2009, i.e. 20 years after the inception of the English screening 
programme, to assess the on-going impact of the NHS BSP on breast cancer mortality. The study was 
set up in the London region (England), which has a dynamic population with a high degree of 
cultural, ethnic and socio-economic diversity with screening coverage consistently lower than the 
national average (22). 
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Material & Methods 
Study design 
A case-control study nested with the NHS BSP was set up. We targeted women residing in the 
London region, who had been invited to participate in the NHS BSP from 1988 onwards, and who 
had not expressed dissent to their records being used for evaluation purposes. In England, patients 
have the opportunity to specify that their primary healthcare data cannot be shared with third 
parties for the purposes of audit, research or commerce. Patients who made such a stipulation were 
excluded from this study. 
This study is part of a protocol for the on-going evaluation of the English NHS BSP and has received 
all relevant approvals (details published in (23)). 
All women registered as having primary breast cancer as the leading cause of death on their death 
certificate (rather than as contributing to death or with no specified leading cause), as having died 
aged 47-89 between the 1st of January 2008 and the 31st of December 2009 and as having been first 
diagnosed with primary breast cancer (invasive) aged 47-89 and since 1990 were selected as cases.  
Each case was matched to one or two general population controls sampled from the National Health 
Applications and Infrastructure Services (NHAIS) system of the Health & Social Care Information 
Centre (HSCIC) national database: each control was alive at the case’s date of death and had not 
been diagnosed with breast cancer prior to the case’s date of first diagnosis, to allow for equal 
screening opportunity. The controls were matched to cases according to date of birth, within 6 
months in either direction, to account for the increased incidence of breast cancer with age, and 
were registered in the same NHAIS area (English geographical screening entity), within London, as 
the case, at the case’s date of first diagnosis. 
Controls were given a pseudo-diagnosis equal to the date of first diagnosis of their matched case. 
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All cases and controls had been invited to take part in the NHS BSP at least once prior to their first 
diagnosis/pseudo-diagnosis date. For cases who had been registered on the local NHAIS system by 
age 47, or who had records of cervical screening prior to age 47, which could be taken to imply that 
they had been registered with the National Health Service (NHS), controls were selected who had 
either specification. For cases who had not been registered on the local NHAIS system by age 47, nor 
had records of cervical screening prior to age 47, controls were selected who had received a first 
invitation to breast screening within 6 months either side of the case's date of first invitation to 
breast screening. This strategy ensured that both cases and controls received similar number of 
invitations. 
Data collection 
Cause of death was obtained from the Office for National Statistics (ONS) and linked to the primary 
breast cancer occurrences data extracted from the National Cancer Data Repository (NCDR) by the 
National Cancer Intelligence Network (NCIN) London. 
Screening history data were traced on the NHAIS system and linked to breast cancer data. In the UK, 
users of the National Health Service have a unique NHS number. We ensured accurate linkage using 
this number in addition to the woman’s date of birth. Only breast screens with corresponding 
invitation dates sent at ages 47-73 and prior to date of diagnosis/pseudo-diagnosis were included in 
the analysis. Mammograms performed outside of the screening programme are not registered in 
this database.  
All data were processed in accordance with NHS Information Governance guidelines (NHS IG Toolkit, 
https://www.igt.hscic.gov.uk/). 
Power calculation 
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The odds ratio (OR) for breast cancer mortality associated with ever attending breast screening was 
assumed to be equal to the meta-analysis estimate of 0.70 obtained by Broeders et al. (7). With two 
controls per case, and an estimated number of discordant pairs of 33%, 800 cancer deaths and 1,600 
general population controls would provide over 90% power to detect such an effect size at the 5% 
significance level using a 2-sided test (24). 
Statistical methods 
Regression modelling 
Cases and controls were compared with respect to attendance at breast screening using conditional 
logistic regression. Matching factors, i.e. date of birth and NHAIS area registration, were controlled 
for in the design. Various measures of exposure to mammographic screening were assessed, 
including ever being screened, time since last screen and number of screens attended. The extent of 
self-selection and lead time (exposure opportunity) biases were investigated. 
Self-selection 
The OR (߰) was  corrected for self-selection bias using the formula derived by Duffy et al. (19) where 
a correction factor ‘ܦ௥’ is defined as the relative risk of breast cancer death for non-attenders 
compared to the not invited: 
߰ᇱ = ߰. ݌. ܦ௥  (1 − (1 − ݌). ܦ௥⁄ ) ,  
where ݌ is the proportion of control women who attend the screening invitation. ‘ܦ௥’ was estimated 
using the relative risk of breast cancer death in non-attenders to the cervical screening programme 
compared to the general population, adjusted for confounding of cervical screening attendance with 
breast screening attendance (see details in (25)). 
For analyses of time since last screen stratified by age at first diagnosis, the logistic regression was 
adjusted for contemporary attendance at cervical screening prior to diagnosis using a 3-category 
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variable in order to partially account for self-selection: “Never screened”, “Formerly screened (> 60 
months)” and “Currently screened (0 - 60 months)”. 
Lead time (Exposure opportunity) 
Although we adopted a selection strategy which allowed for similar opportunity in terms of 
invitation to breast screening, controls assigned to screen-detected cases may not have had an equal 
opportunity to attend the last invitation prior to date of diagnosis/pseudo-diagnosis as their 
matched case. 
As controls are given a pseudo-diagnosis date equal to that of their matched case diagnosis and  as 
screening history is only considered up to that date, the fact that cases have necessarily a diagnosis 
of breast cancer while controls do not, induces an artificially higher retrospective probability of 
screening exposure in the cases, and results in a bias against screening (26). This bias can be 
assumed to be minimal when assessing the effect of ever having been screened, due to the 
programme being a mature one, with approximately 6 incidence screens (over 20 years). 
However, when assessing the effect of number of screens or time since last screen, this bias cannot 
be ignored. To compensate for the lead time owing to cancer screen detection among cases, a 
sensitivity analysis was performed where the pseudo-diagnosis date of the controls matched to each 
screen-detected case was postponed by 1 year to allow the control women to be screened for a 
duration comparable to the preclinical detectable phase/clinical lead time (27), and by 3 years to 
allow for an extra screening round (4). 
All statistical analyses were performed using the statistical softwares STATA version 12.1 
(www.stata.com) and R version 2.13.0 (The R Foundation for Statistical Computing, www.r-
project.org/foundation) 
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Results 
Data description 
1,493 breast cancer deaths were registered in London during 2008-2009; of these, 1,471 were traced 
in the NHAIS database. Sixty-two percent of these women (917 cases) had breast screening 
registration records prior to first diagnosis and 916 were matched to at least one control who had 
not been diagnosed with breast cancer at the date of first diagnosis of their matched case (Figure 1). 
Forty-seven matched sets were excluded because either the case or both controls had not been 
invited to the NHS BSP at least once prior to the case’s date of first diagnosis, or because the date of 
first invitation for both controls fell more than 4 years distant from the case first invitation. 
Therefore, 869 cases and 1,642 controls (773 cases matched to 2 controls and 96 matched to 1 
control) remained in the dataset used in the main analysis.  
Over 80% of women in our dataset selected were diagnosed from the year 2000 onwards (Table 1a). 
The cases’ median age at diagnosis was 63.1 and median age at death 69.1 years old. 
Median age at first NHS BSP invitation was 52.6 for both cases and controls, and both groups 
received a median number of invitations to breast screening of 3. Among participants in breast 
screening, median ages at first (53.9 for controls and 54.4 for cases) and last (60.7 for controls and 
60.8 for cases) breast screens were similar, although proportionally more controls attended their 
first (70.5% versus 62.8% for cases) and last (68.5% versus 61.6% for cases) invitation (Table 1b). In 
addition, the proportion of women who never attended screening was larger for cases (25.3% versus 
18.3% for controls) and was mirrored by a larger proportion of control women having attended 
screening more than once (53.6% versus 46.7% for cases, Table 1b). 
Effect of attendance at screening after adjusting for self-selection bias and underlying attendance 
rate 
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Breast cancer mortality was 35% lower among attenders at breast screening compared with those 
who never attended (OR=0.65, 95%CI 0.53-0.80; Table 2). Correcting for self-selection bias had little 
impact on the overall OR (corrected OR=0.61, 95%CI 0.44-0.85 based on a correction factor ܦ௥  of 
0.95, 95%CI 0.74-1.23 and an attendance rate p of 81.7%,(25)). Attendance at last invitation was 
associated with significant but lower mortality reduction (corrected OR=0.74, 95%CI 0.62-0.90, Table 
2), as this population of attenders was enriched in screen-detected fatal cancers. 
Among women who had been invited at least twice, attending breast screening more than once 
conferred greater benefit (corrected OR=0.66, 95%CI 0.45-0.98) than attending once only (corrected 
OR=0.88, 95%CI 0.62-1.25) compared to never being screened. 
The beneficial effect of ever attending an invitation was slightly more pronounced in the more 
recent years, i.e. among cases diagnosed since 2000 (corrected OR=0.54, 95%CI 0.36-0.81). 
Effect of time since last attendance at breast screening according to age at first diagnosis 
Overall, the breast cancer mortality reduction decreased with time since last screen, from a 66% 
reduction (OR=0.34, 95%CI 0.25-0.46) for last attendance in the 2 years prior to date of 
diagnosis/pseudo-diagnosis (excluding the first 3 months to account for most of the screen-detected 
cancers) to a 20% reduction for last attendance more than 5 years prior to diagnosis (OR=0.80, 
95%CI 0.60-1.06, Table 3). This decreasing trend was seen for all age categories investigated. 
Attendance within the last 3 years resulted in a 60% reduction in mortality (OR=0.40, 95%CI 0.31-
0.51, Table 3) with an even greater benefit observed in the older age group (70+, OR=0.33, 95%CI 
0.14-0.73, Table 3). Adjustment for attendance at cervical screening, as a means of addressing self-
selection, had little effect on the ORs (data not shown). 
There were only two notable differences in effect with respect to age. First, for attendance within 
the last 2 years, the reduction in mortality was less pronounced among women diagnosed at a 
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younger age (OR=0.42, 95%CI 0.29-0.62 for diagnosis age 47-59, and OR=0.29, 95%CI 0.17-0.50 for 
diagnosis age 60-69, Table 3). Second, in those aged over 70, there was still a substantial (30%) 
reduction in mortality associated with last attendance being more than 5 years prior to date of 
diagnosis/pseudo-diagnosis (OR=0.70, 95% CI 0.47-1.04). 
Sensitivity analyses were performed which allowed for the controls of screen-detected cases to have 
the opportunity to be screened in the 3 years following the case’s date of first diagnosis in order to 
account for any exposure opportunity bias (an additional 252 invitations were received by the 
controls and 179 were attended). Extending the period of screening opportunity for the controls 
only impacted the ORs among younger women in terms of benefit of attendance at screening 
beyond 3 years prior to diagnosis, showing a 10-15% increase in mortality reduction, e.g. from 0.75 
down to 0.67 for attendance in the last 3 to 5 years (Table 3). 
Discussion 
The aim of our study was to assess the current impact of attendance at a national breast screening 
programme on breast cancer mortality in an urban region (London) with relatively low screening 
coverage compared to the national average (i.e. 65% compared to 77% national average in 2008-09 
for women age 50-70,(22)). 
We found that attending breast screening at least once reduced the mortality risk by 35% (for a 
81.7% ‘ever attendance’ rate among controls), and that this estimate was not affected by self-
selection. Attending in the last 3 years (prior to the case’s date of diagnosis/pseudo-diagnosis) 
resulted in around 60% reduction in mortality. The benefit of attending screening was slightly larger 
in cancers diagnosed since 2000. 
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Our unadjusted estimate of mortality risk reduction for ever attending breast screening was very 
close to a previous case-control study undertaken in another region of the UK, i.e. a 38% crude 
reduction in Wales for a 77% ‘ever attendance’ rate among controls (28). Our estimate was also very 
similar to the estimate obtained for a case-control study run in the London region 20 years prior: a 
33% crude reduction was observed for a 72% ‘ever attendance’ rate among controls (29). The much 
larger crude reduction observed in the UK East Anglia region (65% reduction for a 89% ‘ever 
attendance’ rate among controls,(30)) is likely to have been due to the short survival of the selected 
cases (diagnosis and death during the same time period). 
Our unadjusted estimate of mortality risk reduction for ever attending breast screening was also 
lower than the unadjusted estimate obtained in Iceland (41% reduction for a 62% ‘ever attendance’ 
rate among controls,(31)), in five Italian regions (56% reduction in mortality for a 62% ‘ever 
attendance’ rate among controls,(32)), and in two Australian regions (41% reduction for a 62% ‘ever 
attendance’ rate among controls,(33) and 49% reduction for a 56% ‘ever attendance’ rate among 
controls,(20)). 
Attendance at breast screening in the 3 years prior to case diagnosis (screen-detected cancers 
excluded) led to a 60% reduction in mortality: this estimate is not widely at variance with results 
obtained for recent attendance in a number of Dutch regional studies. They observed between 30% 
and up to 70% reduction in seven different regions (21),(34),(35): in the most urban region with 
relative lowest attendance rate (SBBZWN), the unadjusted reduction was 56%, an estimate indeed 
very close to our estimate of effect of attendance in the 3 years prior to case diagnosis. The 
proportion of controls who had never responded to an invitation in our study was very similar to the 
proportion by Otto et al. (35), i.e. 18.3% versus 18.1%); the proportion of cases who never attended 
was however far larger in the Netherlands (35.9% compared to 25.3% in our study), as was the 
proportion of screen-detected cases (29.8% versus 18.5%). 
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In agreement with our results, other case-control studies have reported increased benefit with 
number of screens, and decreased benefit with increasing time since last breast screen, i.e.  in the 
UK (28),(30) and in early (prior to 1990) studies set up in Utrecht, Netherlands (36),(37). 
The increased benefit of attendance at breast screening with age at first diagnosis was observed 
previously (20),(33),(35). Our estimate for the 70-89 age group may be subject to strong self-
selection bias, as after 70 years old, one would have to self-refer to be screened. This fact may also 
be reflected in the difference seen between the OR of attendance at last invitation and the OR of 
attendance in the last 3 years, as women diagnosed over the age of e.g. 73 may not have been 
invited in the last 3 years. It is worth noting that our estimated mortality reductions did not vary 
substantially by age, suggesting that from age 47 to well over age 70, there is a similar relative 
benefit from mammography screening. 
The breast cancer mortality reductions observed in association with screening in the RCTs of 
mammography may not automatically apply in our current epoch of effective adjuvant systemic 
therapy and standardised management of breast cancer. It is therefore important for both 
healthcare providers and women invited to screening to estimate the effect of current screening 
programmes on risk of death from breast cancer. In this study, we assessed the effect of the NHS 
Breast Screening Programme on deaths from breast cancer in 2008-09. The majority of tumours 
were diagnosed since the year 2000, unequivocally in this adjuvant therapy epoch. 
The fact that we observed a slightly larger effect of screening from 2000 onwards may be a 
consequence of the roll-out for the adoption of two-view mammography in all breast screening units 
at every attendance from 2000 (11), or of the extension of the programme to include women aged 
65-70 from 2001 (3). In addition, changes in breast cancer management, such as the introduction of 
new referral and practice guidelines with respect to breast symptoms and the implementation of 
MDTs alongside screening in more recent years may be a contributory factor (12),(38). 
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We felt that an approach which uses contemporary data was desirable to estimate the degree and 
effect of self-selection in our study population. We chose to use a new approach based on 
contemporary attendance at cervical screening  to estimate the underlying risk of breast cancer 
death in the different screening groups compared (for details, see (25)). Our results suggest that self-
selection bias in the London region is limited (close to 1.0) when assessing the effect of screening on 
breast cancer mortality among the general population. This observation is in agreement with 
findings by other authors who used contemporary data, including in the UK among women aged 40-
49 (39). Cases and controls were drawn from the same cohort of women invited to screening and 
their screening histories were retrieved from the same database; in addition they were selected 
from within the same small geographical area; this may have increased similarities in terms of 
demographic and socio-economic characteristics, consequently accounting for some of the self-
selection. 
In our study, cases and controls were not matched on the number of invitations to breast screening 
they received, and the screening database does not record round of invitation. Sensitivity analyses 
did not expose residual opportunity bias for controls, suggesting the design adequately ensured 
equal screening opportunity among controls. In the extension of this case-control evaluation to the 
rest of England, we will be selecting controls who receive their first invitation within 6 months of the 
case’s date of first invitation. 
We report on the findings of the largest case-control study assessing the impact of participation in 
the English national breast screening programme. Cases and controls were drawn from the same 
underlying cohort of the women invited to screening in the most populated region of the country. 
In this urban population, attendance at breast screening led to a decrease in breast cancer mortality 
of 35% which is higher than the reported 20% reduction observed in the RCTs of mammographic 
screening, but lower than the approximate 50% reductions reported using various case-control 
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designs in other regions of Europe and Australia with different population characteristics (reviewed 
in (7),(20),(21)). Self-selection was observed to be minimal. 
Our results provide evidence of a clear beneficial effect of the NHS BSP on the risk of mortality from 
breast cancer in an area of England known to have low coverage. We found no evidence suggesting 
that attendance at this mature screening programme provided women with a lesser benefit in the 
more recent years. 
Overall, our results suggest that community breast screening programmes provide their expected 
benefit in terms of reducing the risk of breast cancer death among women participating. 
Mammography is an important tool for reducing breast cancer mortality and its impact could be 
increased by encouraging regular attendance. 
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Tables 
Table 1  Patient demographics and screening history by case-control status 
Table 1a. Patient demographics 
 
 
 
Controls
(N = 1,642) 
Cases
(N = 869) 
Breast cancer diagnosis & death  
Year of first diagnosis/pseudo-diagnosis (Count, %) 
1990-1994 57 (3.5) 31 (3.6) 
1995-1999 216 (13.2) 113 (13.0) 
2000-2004 483 (29.4) 256 (29.5) 
2005-2009 886 (54.0) 469 (54.0)
Age category at first diagnosis/pseudo-diagnosis (Count, %)
47 - 54 260 (15.8) 133 (15.3) 
55 – 59 377 (23.0) 196 (22.6) 
60 – 64 296 (18.0) 157 (18.1) 
65 - 69 267 (16.3) 145 (16.7)
70 – 74 244 (14.9) 129 (14.8)
75 - 89 198 (12.1) 109 (12.5) 
Median age at first diagnosis/pseudo-diagnosis in years (range) 63.0 (48.0 – 87.8) 63.1 (48.0 – 87.8) 
Median age at death in years (range)  NA 69.1 (51.6 – 88.0) 
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Table 1b. Patient screening history 
 
 
 
Controls
(N = 1,642) 
Cases
(N = 869) 
Breast screening history  
Number of screening invitations (Count, %)   
1 407 (24.8) 239 (27.5) 
2 398 (24.2) 192 (22.1) 
 3 360 (21.9) 173 (19.9)
4 235 (14.3) 135 (15.5)
  5+ 242 (14.7) 130 (15.0) 
Median number of screening invitations (range)  3.0 (1 - 9) 3.0 (1 - 8) 
Median age at first screening invitation in years (range) 52.6 (47.3 – 71.9) 52.6 (47.0 – 72.1) 
Attendance at first screening invitation 
Did not attend 485 (29.5) 323 (37.2)
        Attended 1,157 (70.5) 546 (62.8) 
Median age at last screening invitation in years (range) 61.2 (47.3-73.8) 61.2 (47.3-73.9) 
Attendance at last screening invitation   
Did not attend 518 (31.6) 334 (38.4)
        Attended 1,124 (68.5) 535 (61.6)
   
Number of screens (Count, %)   
                             0 (Never screened) 300 (18.3) 220 (25.3) 
1 462 (28.1) 243 (28.0)
  1+ 880 (53.6) 406 (46.7)
Median number of screens (range)  2.0 (0 – 7) 1.0 (0 – 8) 
Median time since last screen (range)  
– among compliers 
2.3 yrs (0 days – 19.7 yrs) 2.4 yrs (0 days – 20.0 yrs) 
Median age at first screen in years (range) 
– among compliers 
53.9 (47.6 – 72.2) 54.4 (47.3 – 71.0)
Median age at last screen in years (range) 
– among compliers 
60.7 (47.6 – 73.9) 60.8 (49.1 – 73.9)
   
Cervical screening history  
Attendance at cervical screening (Count, %)   
Never screened 355 (21.6) 200 (23.0) 
Formerly screened (>60 months) 517 (31.5) 284 (32.7)
Currently screened (0-60months) 770 (46.9) 385 (44.3)
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Table 2  Conditional odds ratios (OR) of mortality from primary breast cancer for attendance at breast screening 
 Odds ratio
(95% CI, p-value) 
Exposure to screening 
 
 
Cases / Controls Self-selection
bias correction factor ܦ௥  (a) 
(95%CI) 
Primary analysis +3 years exposure
Invited at least once    
Never screened 220 / 300 1.00 (-) 1.00 (-)
Number of screen ≥ 1 649 / 1342 None 0.65 (0.53 - 0.80, <0.001) 0.62 (0.50 - 0.76, <0.001)
 ܦ௥ = 0.95 (0.74 – 1.23) 0.61 (0.44 - 0.85, 0.004) 0.59 (0.42 - 0.82, 0.002)
Did not attend last invitation 334 / 518 1.00 (-) 1.00 (-)
Attended last invitation 535 / 1124 None 0.73 (0.62 - 0.88, 0.001) 0.72 (0.60 - 0.86, <0.001)
 ܦ௥ = 1.01 (0.93 – 1.11) 0.74 (0.62 - 0.90, 0.002) 0.73 (0.60 - 0.90, 0.003)
Invited at least twice     
Never screened 121 / 178  1.00 (-) 1.00 (-) 
Number of screen = 1 103 / 177 None 0.83 (0.59 - 1.18, 0.3) 0.83 (0.59 - 1.17, 0.3) 
  ܦ௥ = 1.03 (0.94 – 1.13)(b) 0.88 (0.62 – 1.25, 0.5) 0.88 (0.62 – 1.25, 0.5) 
Number of screen > 1 406 / 880 None 0.62 (0.47 - 0.82, 0.001) 0.66 (0.51 - 0.87, 0.003)
 ܦ௥ = 1.06 (0.81 – 1.39)(b) 0.66 (0.45 – 0.98, 0.04) 0.71 (0.49 – 1.03, 0.07)
(a) Self-selection correction of OR using data on attendance at the cervical screening programme (described in (25)) 
(b) Women were assumed to have been invited at least twice to the cervical screening programme in order to derive ܦ௥. 
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Table 3  Conditional odds ratios (OR) of mortality from primary breast cancer according to 
time since last breast screen: correction for lead time (exposure opportunity) bias 
Analyses were adjusted for attendance at cervical screening(a). 
 
   Odds Ratio 
(95% CI, p-value) 
Age at case 
first diagnosis 
Time since last 
breast screen 
Cases / Controls Primary analysis + 3 years exposure
47-89     
 Never screened  220 / 300 1.00 (-) 1.00 (-) 
 Screened 3-36 months 215 / 716 0.40 (0.31-0.51, <0.001) 0.39 (0.30-0.50, <0.001)  
 Screened >60 months 212 / 381 0.80 (0.60-1.06, 0.1) 0.78 (0.59-1.04, 0.08)
 Screened 36-60 months  61 / 138 0.62 (0.42-0.91, 0.02) 0.60 (0.41-0.88, 0.009)
 Screened 24-36 months 88 / 240 0.48 (0.35-0.67, <0.001) 0.47 (0.34-0.65, <0.001)
 Screened 3-24 months  127 / 476 0.34 (0.25-0.46, <0.001) 0.33 (0.25-0.45, <0.001)
 Screened ≤3 months  161 / 107 2.66 (1.84-3.87, <0.001) 2.54 (1.74-3.70, <0.001)
47-59     
 Never screened  98 / 138 1.00 (-) 1.00 (-) 
 Screened 3-36 months 107 / 365 0.45 (0.32-0.65, <0.001) 0.42 (0.29-0.61, <0.001) 
 Screened >60 months 12 / 20 0.75 (0.34-1.66, 0.5) 0.64 (0.30-1.40, 0.3) 
 Screened 36-60 months  19 / 41 0.75 (0.40-1.40, 0.4) 0.67 (0.36-1.25, 0.2) 
 Screened 24-36 months 34 / 99 0.54 (0.33-0.89, 0.02) 0.50 (0.30-0.82, 0.006) 
 Screened 3-24 months  73 / 266 0.42 (0.29-0.62, <0.001) 0.40 (0.27-0.60, <0.001) 
 Screened ≤3 months  93 / 73 2.48 (1.52-4.04, <0.001) 2.42 (1.47-4.01, 0.001) 
60-69     
 Never screened  57 / 77 1.00 (-) 1.00 (-) 
 Screened 3-36 months 96 / 306 0.35 (0.22-0.57,  <0.001) 0.35 (0.22-0.57, <0.001) 
 Screened >60 months 52 / 74 0.97 (0.54-1.72, 0.9) 0.98 (0.55-1.76, 0.96) 
 Screened 36-60 months  34 / 77 0.59 (0.32-1.08, 0.09) 0.59 (0.32-1.08, 0.08) 
 Screened 24-36 months 46 / 119 0.46 (0.26-0.80, 0.006) 0.46 (0.26-0.80, 0.006) 
 Screened 3-24 months  50 / 187 0.29 (0.17-0.50, <0.001) 0.29 (0.17-0.50, <0.001) 
 Screened ≤3 months  63 / 29 3.86 (1.95-7.64, <0.001) 3.47 (1.75-6.88, 0.001)
70-89     
 Never screened  65 / 85 1.00 (-) 1.00 (-) 
 Screened 3-36 months 12 / 45 0.33 (0.14-0.73, 0.006) 0.33 (0.14-0.73, 0.006) 
 Screened >60 months 148 / 287 0.70 (0.47-1.04, 0.07) 0.70 (0.47-1.04, 0.07) 
 Screened 36-60 months  8 / 20 0.54 (0.21-1.35, 0.2) 0.54 (0.21-1.35, 0.2) 
 Screened 24-36 months 8 / 22 0.46 (0.18-1.16, 0.1) 0.46 (0.18-1.16, 0.1)
 Screened 3-24 months  4 / 23 0.18 (0.05-0.65, 0.009) 0.18 (0.05-0.65, 0.009)
 Screened ≤3 months  5 / 5 1.58 (0.33-7.56, 0.6) 1.58 (0.33-7.56, 0.6)
(a) Self-selection adjustment using and attendance at cervical screening. See categorization in Table 1b. 
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